KSR

KSR^®
Potassium Chloride
Potassium supplement

Composition
Each film-coated SR tablet contains Potassium Chloride 600 mg.

Mode of action
KSR is a film-coated preparation of potassium chloride formulated for slow release.
Each tablet contains 600 mg of potassium chloride which is equivalent to 8 milli-equivalents each of Potassium (K⁺) and Chloride (Cl^-). The slow and sustained release over a period of 6 hours precludes high concentrations of potassium chloride against a localized area of the gut wall which might irritate or damage the mucosa. The sustained release provides conditions of maximum gastric tolerance and effective absorption for the treatment of all types of potassium deficiency, whether hypochloraemic or hypokalaemic alkalosis. KSR does not alter normal kidney function; can be used in all age groups; replaces the essential chloride anion and potassium and so prevents hypochloraemic alkalosis. During KSR administration, laboratory monitoring of serum electrolyte levels should be done periodically.

Indications
For treatment and specific prevention of hypokalaemia.

Dosage and administration
An average dose is 1 or 2 tablets two or three times daily, each tablet swallowed whole with a little water, preferably during meals. Where KSR is administered routinely with an average daily maintenance dose of an oral diuretic agent, 1 or 2 tablets daily may be sufficient.

Warnings
If a patient under treatment with KSR develops severe vomiting, severe abdominal pains or flatulence, or gastrointestinal haemorrhage, the preparation should be withdrawn at once. To prevent the risk of hyperkalaemia, potassium supplements should not be administered with potassium sparing diuretic agent such as spironolactone, triamterene or amiloride. In case of metabolic acidosis, hypokalaemia should not be treated with potassium chloride but with a potassium salt containing an alkalizing anion (e.g. potassium bicarbonate).

Precautions
In patients with impaired renal function, special care should be exercised when prescribing potassium salts because of the risk of hyperkalaemia. The serum electrolytes should be monitored in these patients and also in patients with congestive heart failure, especiaily if under treatment with digitalis, in whom hypokalaemia should be avoided.

Adverse reactions
Oral potassium preparations can provoke gastrointestinal disturbances (e.g. nausea, vomiting, abdominal pain, diarrhoea). In rare cases, KSR may also cause these side-effects. In this event, reduction in dosage or withdrawal of drug may be necessary.

Contraindications
Advanced renal failure, untreated Addison's disease, acute dehydration, hyperkalaemia, in the presence of obstruction in the digestive tract (e.g. resulting from compression of the oesophagus due to dilation of the left atrium or from stenosis of the gut). The administration of KSR in such a situation could be conceivably give rise to ulceration or perforation.

Presentations
Bottle of 100 film-coated SR tablets
Box of 10 x 10 film-coated SR tablets in strip

Storage
Store in a dry place, below 25°C

Harus dengan resep dokter

Manufactured by
PT. Merck Tbk., Jakarta

Reg. Nos.
DKL 0315807714A1 (in strip)
DKL 0315807714A2 (in bottle)

Share this :